{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:31:55Z","timestamp":1759332715102},"reference-count":28,"publisher":"Georg Thieme Verlag KG","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study was to evaluate the efficacy of cabergoline in normalizing\n                    plasma IGF-I levels in acromegaly patients with elevated IGF-I levels after\n                    surgery and\/or SRL therapy. Acromegaly patients (n: 143) were evaluated\n                    retrospectively. Patients with elevated IGF-I levels after surgery\n                    and\/or SRLs therapy and a fixed dose of SRLs treatment for the last six\n                    months with no history of radiotherapy in the last three years were included in\n                    the study (n: 12). Previous treatment regimens, baseline PRL and IGF-I levels\n                    (ULNR), sella MRI, and immunohistochemical findings were evaluated. Cabergoline\n                    was used as an add on (n: 11) or single medical treatment (n: 1). The median\n                    duration of treatment with SRL alone was 12 months (range 6\u201348 months).\n                    The mean IGF-I value before cabergoline therapy was 1.45\u00b10.4 ULNR. The\n                    mean cabergoline dose and duration of treatment were\n                    1.55\u00b10.75\u2009mg\/week and 9\u00b16.3 months,\n                    respectively. IGF-I normalization was only achieved in patients with serum IGF-I\n                    concentration&lt;1.5\u00d7ULNR before the onset of cabergoline treatment\n                    (n: 9). In some of the patients with IGF-I normalization, baseline prolactin\n                    levels were normal (n: 3). Immunopositivity for prolactin in adenoma tissue was\n                    found in three patients with IGF-I normalization. Cabergoline therapy is\n                    effective in the normalization of IGF-I levels even in normoprolactinemic\n                    acromegaly patients when IGF-I levels are mildly or moderately elevated during\n                    SRL therapy.<\/jats:p>","DOI":"10.1055\/a-1930-6585","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T22:35:22Z","timestamp":1665182122000},"page":"664-670","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Cabergoline Treatment on Disease Control in Acromegaly\n                    Patients"],"prefix":"10.1055","volume":"54","author":[{"given":"Hulya","family":"Hacisahinogullari","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and\n                    Metabolism, Istanbul University, Istanbul Faculty of Medicine, Istanbul,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulsah Yenidunya","family":"Yalin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and\n                    Metabolism, Istanbul University, Istanbul Faculty of Medicine, Istanbul,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem Soyluk","family":"Selcukbiricik","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and\n                    Metabolism, Istanbul University, Istanbul Faculty of Medicine, Istanbul,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurdan","family":"Gul","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and\n                    Metabolism, Istanbul University, Istanbul Faculty of Medicine, Istanbul,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bilge","family":"Bilgic","sequence":"additional","affiliation":[{"name":"Department of Pathology, Istanbul University, Istanbul Faculty of\n                    Medicine, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse Kubat","family":"Uzum","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and\n                    Metabolism, Istanbul University, Istanbul Faculty of Medicine, Istanbul,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Refik","family":"Tanakol","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and\n                    Metabolism, Istanbul University, Istanbul Faculty of Medicine, Istanbul,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ferihan","family":"Aral","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and\n                    Metabolism, Istanbul University, Istanbul Faculty of Medicine, Istanbul,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,10,7]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1009965803750","article-title":"Epidemiology of acromegaly","volume":"2","author":"I M Holdaway","year":"1999","journal-title":"Pituitary"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11102-015-0701-2","article-title":"Incidence and prevalence of acromegaly in a large US health plan database","volume":"19","author":"T Burton","year":"2016","journal-title":"Pituitary"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1530\/EJE-15-0189","article-title":"The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide\n                    population-based study","volume":"173","author":"T T Agustsson","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","article-title":"Prevalence and incidence of pituitary adenomas: a population based study in\n                    Malta","volume":"16","author":"M Gruppetta","year":"2013","journal-title":"Pituitary"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"S Melmed","year":"2009","journal-title":"J Clin Invest"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1210\/er.2009-0033","article-title":"Mortality in patients with pituitary disease","volume":"31","author":"M Sherlock","year":"2010","journal-title":"Endocr Rev"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2014-2670","article-title":"Successful mortality reduction and control of comorbidities in patients with\n                    acromegaly followed at a highly specialized multidisciplinary clinic","volume":"99","author":"M Mercado","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on\n                    mortality in acromegaly","volume":"159","author":"I M Holdaway","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1007\/s11102-015-0657-2","article-title":"IGF-1 levels across the spectrum of normal to elevated in acromegaly:\n                    relationship to insulin sensitivity, markers of cardiovascular risk and body\n                    composition","volume":"18","author":"T J Reid","year":"2015","journal-title":"Pituitary"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"L Katznelson","year":"2014","journal-title":"J. Clin. Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s00701-017-3318-6","article-title":"Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a\n                    systematic review of outcomes and complications","volume":"159","author":"C J Chen","year":"2017","journal-title":"Acta Neurochir (Wien)"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1210\/jc.2013-3757","article-title":"Acromegaly clinical trial methodology impact on reported biochemical efficacy\n                    rates of somatostatin receptor ligand treatments: a metaanalysis","volume":"99","author":"J D Carmichael","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting biochemical control response rates with first-generation\n                    somatostatin analogues in acromegaly","volume":"19","author":"A Colao","year":"2016","journal-title":"Pituitary"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11102-012-0445-1","article-title":"Growth hormone granulation pattern and somatostatin receptor subtype 2A\n                    correlate with postoperative somatostatin receptor ligand response in\n                    acromegaly: a large single center experience","volume":"16","author":"J Brzana","year":"2013","journal-title":"Pituitary"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1530\/ERC-16-0356","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin\n                    analogs in acromegaly","volume":"23","author":"I Potorac","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients\n                    with inadequately controlled acromegaly (PAOLA): a randomised, phase 3\n                    trial","volume":"2","author":"M R Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0022-510X(81)90081-2","article-title":"Dopaminergic inhibition of growth hormone and prolactin release during\n                    continuous in vitro perifusion of normal and adenomatous human pituitary","volume":"49","author":"N F Lawton","year":"1981","journal-title":"J Neurol Sci"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1126\/science.288.5463.154","article-title":"Receptors for dopamine and somatostatin: formation of heterooligomers with\n                    enhanced functional activity","volume":"288","author":"M Rocheville","year":"2000","journal-title":"Science"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"L Sandret","year":"2011","journal-title":"J. Clin. Endocrinol Metab"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00418-008-0472-1","article-title":"Pathology of the human pituitary adenomas","volume":"130","author":"R Y Osamura","year":"2008","journal-title":"Histochem Cell Biol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/eje.1.02326","article-title":"Pathohistological classification of pituitary tumors: 10 years of experience\n                    with the German Pituitary Tumor Registry","volume":"156","author":"W Saeger","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1210\/jcem.83.2.4556","article-title":"Cabergoline in the treatment of acromegaly: a study of 64 patients","volume":"83","author":"R Abs","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11102-010-0272-1","article-title":"Role of the addition of cabergoline to the management of acromegalic patients\n                    resistant to longterm treatment with octreotide LAR","volume":"14","author":"L Vilar","year":"2010","journal-title":"Pituitary"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000317314","article-title":"Short- and long-term efficacy of combined cabergoline and octreotide treatment\n                    in controlling IGF-I levels in acromegaly","volume":"92","author":"P Mattar","year":"2010","journal-title":"Neuroendocrinology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.17925\/EE.2019.15.1.30","article-title":"Functioning pituitary adenomas \u2013 current treatment options and emerging\n                    medical therapies","volume":"15","author":"E V Varlamov","year":"2019","journal-title":"Eur Endocrinol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1074\/jbc.275.11.7862","article-title":"Subtypes of the somatostatin receptor assemble as functional\n                    homo-heterodimers","volume":"275","author":"M Rocheville","year":"2000","journal-title":"J Biol Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1210\/jc.2012-1833","article-title":"No evidence of a detrimental effect of cabergoline therapy on cardiac valves in\n                    patients with acromegaly","volume":"97","author":"L Maione","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1530\/EJE-18-0667","article-title":"Management of endocrine disease: mpulse control disorders in patients with\n                    hyperpolactinemia treated with dopamine agonists: how much should we worry?","volume":"179","author":"M Barake","year":"2018","journal-title":"Eur J Endocrinol"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1930-6585.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T22:36:40Z","timestamp":1665182200000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1930-6585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10,7]]},"published-print":{"date-parts":[[2022,10]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1930-6585","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}